Skin Reports in 114 TDI Foam-Plant Workers

November 12, 2026

Doctor’s Notes · Life in Motion · Evidence Review

Editorial disclosure: The featured image is an AI-created illustration of a fictional work or daily-life scene. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.

Reader question: What did symptom, blood and patch-test findings show in 114 TDI foam-plant workers?

Study snapshot

Study element	Reported detail
Population	114 employees at a flexible polyurethane-foam manufacturing plant, including production and nonproduction workers.
Design	NIOSH cross-sectional workplace investigation using questionnaires, antibody testing in 100 workers and diisocyanate patch testing in 26 symptomatic workers.
Comparator	Production-line workers were compared with nonproduction employees.
Timepoint	One workplace investigation; no longitudinal follow-up.
Key result	Production workers were more likely to report skin problems than nonproduction workers (prevalence-rate ratio 2.66, 95% CI 1.14–16.32; p=0.02). Two of 100 blood samples had TDI-specific IgG, none had specific IgE, and none of 26 patch-tested workers reacted to the diisocyanate panel.
Funding/conflict context	The investigation was conducted by NIOSH; the indexed abstract does not list additional funding or conflicts. No moisturizer was tested.

What was actually measured?

Production workers were more likely to report skin problems than nonproduction workers (prevalence-rate ratio 2.66, 95% CI 1.14–16.32; p=0.02). Two of 100 blood samples had TDI-specific IgG, none had specific IgE, and none of 26 patch-tested workers reacted to the diisocyanate panel.

The symptom contrast paired with negative diisocyanate patch tests led investigators to consider irritation or an unidentified allergen rather than a demonstrated TDI allergy.

The denominator defines the scope. A patch-test clinic, selected case series, compensation registry, online questionnaire, workplace cohort and general-population survey answer different questions. A percentage from one cannot be silently transferred to the others.

What the result does not prove

Wide confidence interval, small patch-tested subset, cross-sectional timing and lack of complete individual exposure measurements limit precision.

Association, timing and biological plausibility can strengthen an occupational interpretation, but observational evidence cannot automatically establish individual causation. Referral patterns, reporting practices, task mix, protective equipment, nonwork exposures and access to care may all change an estimate.

A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors' conclusions, this interpretation or any product.

Exposure detail matters more than the job label

Workers with the same title can handle different materials for different durations. Useful documentation identifies the exact product or process, the route of contact, glove or PPE material, wetness, friction, heat, dust, splash potential, frequency and how symptoms change away from the task.

A symptom survey can identify a pattern, a clinical examination can refine the differential diagnosis, and patch testing can identify delayed sensitization. None of those steps alone proves that a workplace material caused an individual condition. Clinical relevance still requires a credible exposure and time course.

Questions worth recording

Which task, product, glove, tool, metal, resin, cleanser, food, plant, dust or surface came before symptoms?
Where did the change begin, and did it improve on days away or after a process or PPE change?
How often were hands wet, washed, disinfected, occluded, rubbed, heated or exposed to cold?
Were labels, ingredient information and safety-data sheets reviewed with occupational health?
Did the problem affect dexterity, sleep, pace, attendance, work quality or safety?

Prevention comes before cosmetic care

Substitution, closed systems, local exhaust, splash control, safer cleaning methods, training and correctly selected protective equipment address exposure at its source. Gloves are not automatically protective: material, fit, breakthrough time, sweating, reuse and rubber accelerators all matter.

Do not deliberately place workplace products on skin to test a theory. Persistent, recurrent or spreading symptoms, drainage, fever, breathing symptoms, severe pain, rapidly worsening redness or major loss of function warrant professional evaluation.

Primary research and guidance

Where Dr. Arsy #003 fits

Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema, relieves pain or itch, neutralizes workplace chemicals, is appropriate for every person, or provides pediatric or 24-hour efficacy.

Continue the evidence series

Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace-safety determination.

← Back to Doctor's Notes